Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Match, Credit Suisse, SVB, and Amgen and Encourages Investors to Contact the Firm
17 mars 2023 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
DEADLINE ALERT for SIVB, AMGN, and SBNY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
17 mars 2023 12h00 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, March 17, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
AMGN ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN
15 mars 2023 18h01 HE
|
The Rosen Law Firm PA
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Amgen...
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amgen Inc. (NASDAQ: AMGN)
15 mars 2023 16h00 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Amgen Inc.? If so, please visit Amgen Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your...
CHEMOCENTRYX, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CCXI and Encourages Investors to Contact the Firm
07 août 2022 20h05 HE
|
Bragar Eagel & Squire
NEW YORK, Aug. 07, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
BeiGene Begins Commercializing XGEVA® (Denosumab) in China
30 juin 2020 19h30 HE
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment
02 janv. 2020 08h15 HE
|
BeiGene, LTD.
Amgen Completes Purchase of Approximately $2.8 Billion of BeiGene SharesAnthony C. Hooper, Former Executive Vice President of Global Commercial Operations at Amgen, Joins BeiGene Board of Directors ...
BeiGene Announces Global Strategic Oncology Collaboration with Amgen
31 oct. 2019 16h00 HE
|
BeiGene, LTD.
• Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China • Companies to Jointly Develop 20 Amgen Oncology Pipeline...